Australian doctors can now choose from more than 50 medicinal cannabis products
FreshLeaf Analytics today released Australia's most comprehensive medicinal cannabis product patient and pricing report, and we are pleased to have been part of the process, by providing anonymized prescription data for analysis.
Some of the findings announced by Freshleaf include:
- Products in market increase substantially, up over 500% year on year
- Pricing continues to fall, but CBD has hit a floor
- Patient monthly spend up 11.5%, driven by increased dosages
- 15,000-20,000 new patients to enter the market in 2019
We hope that more hard data about the cost challenges patients face will help to bring costs down over time, and allow more people to get access to medical cannabis products in Australia. Opening up insurance coverage and PBS subsidies would help achieve broader access and lower costs but at the moment that looks some time off.